PIPELINE
For a better future SCM Lifescience will do its best
CoImmune Pipeline
Pipeline
pipeline
preclinical
Phase 1
clinical trial
Phase 2
clinical trial
Phase 3
clinical trial
Acute Lymphocytic Leukemia
Metastatic Kidney Cancer
Non-Hodgkins Lymphoma
Chronic Lymphocytic Leukemia
Colmmune is not our subsidiary company, but a company we invested in. The purpose of this section is just to introduce the pipeline of Colmmune.
Acute lymphocytic leukemia
Proven allogeneic, virus-free CARCIK - CD19 therapy

Primary endpoint : Dose-limiting toxicity: Assessment of the frequency and severity of cytokine release syndrome over a 1-month period
Secondary endpoints : Over all Response Rate (ORR), etc.

  • Indication
    Acute lymphocytic leukemia

    (All)

  • Number of patients
    21 people

    For children and adults

  • Dosing regimen
    STAETING DOSE
    TREATMENT DOSE
    CARCIK - CD19
    DL1*
    DL2
    DL3
    DL4
    Dosage
    1 X 106
    3 X 106
    7.5 X 106
    15 X 106
  • Design
    open label, single group, dose escalation test
clinical trial institution
  • 임상시험 기관 로고
  • 임상시험 기관 로고
Limitations of Autologous CAR-T Therapeutics
  1. 01

    high cost of treatment

  2. 02

    cytokine release syndrome

  3. 03

    Logistics difficulties due to self-treatment

Competitiveness of CAR-CIK
  1. 01

    low cost of treatment

  2. 02

    low cytokine release syndrome

  3. 03

    high efficacy

Sleeping beauty transfer factor system
Utilizing cytokine-induced killer cell technology